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SUMMARY
Background: Antiviral prophylaxis is recommended for HIV positive mothers to prevent mother-to-child trans-
mission of HIV. To date UNAIDS and WHO policy has been based on a study in Thailand which showed a re-
duction in transmission by half with short course AZT (Zidovudine) treatment together with artificial feeding.
We modelled the possible positive and negative effects on child deaths in low and middle resource developing
country settings of two interventions to reduce mother to child transmission (MTCT) of HIV: antenatal testing,
short-course antivirals (zidovudine or nevirapine), firstly with and then without artificial feeding.
Material and methods: Estimates are made of child lives likely to be saved by the programme by age ten years, ba-
lanced against increases in deaths due to more uninfected mothers choosing to use artificial feeds where these are
part of the intervention. Mid-point values for variables affecting the balance of mortality gains and losses are taken
from recent published data for low and middle income developing countries and a sensitivity analysis is undertaken.
Results: In low income settings the use of antivirals alone would result in an estimated gain in child survival of
around 0.36%, representing 360 deaths avoided from a birth cohort of 100,000 by age 10 years.  Adding artifi-
cial feeding could reduce the gain to 0.03% (30 deaths avoided). In middle income settings the gain from anti-
virals alone would be 0.26% but as ‘spill-over’ of artificial feeding to uninfected women was more likely it could
result in a net increase of child deaths of up to 1.08% (1,080 additional deaths). A sensitivity analysis emphasi-
sed this potential for regimens using artificial feeding if progamme participation was low, and under most cir-
cumstances in middle income settings.
Conclusions: HIV testing and use of antivirals by infected mothers, if well implemented, will be effective at a po-
pulation level in reducing MTCT. However the addition of artificial feeding is potentially be a high risk strategy,
especially in middle income countries.
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BACKGROUND
At the end of 1999, more than 33 million people
were estimated to be living with HIV/AIDS [1], al-
most half of whom were women in their reproduc-
tive years. Transmission from these women to their
children is the predominant source of HIV infec-
tion for children, with higher transmission rates re-
ported of up to 30% for African developing coun-
tries - where breast feeding is the norm [2]. In
1999 alone, more than 400,000 children were es-
timated to have been infected globally. Over 90%
of these were born in sub-Saharan Africa, though
the number of cases in India and Southeast Asia
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are rising rapidly [1]. In countries such as Zimba-
bwe Under 5 mortality is thought to have more
than doubled because of HIV [3]. There has there-
fore been an urgent hunt for methods to reduce
mother-to-child transmission of HIV (MTCT).
In 1994 a course of an antiretroviral drug, Zido-
vudine (ZDV), given during pregnancy, labour
and postnatally to the infant, accompanied by ar-
tificial feeds to replace breastfeeding, was found
to reduce MTCT by around two-thirds [4]. Given
the cost and logistical problems of implementing
this programme in developing countries, a short
course version was tested in a trial in Thailand.
This consisted of a package of antenatal maternal
voluntary counselling and testing (VCT), admini-
stering ZDV twice daily during the last 4 weeks
of pregnancy and during labour, and replacing
breastfeeding with free or subsidised artificial fe-
eds, the ‘Thailand’ regime. This trial found the
intervention reduced MTCT by about half [5].
A simplified varient without the artificial feeding
and tested in African settings, the ‘African regi-
me’ still reduced MTCT by nearly 40% [6, 7]. In
another African setting, single dose nevirapine
(NVP) given once during labour and once in the
first 3 days of life to the newborn infants who
continued to breast feed has been recently re-
ported to be effective in Uganda, with a rate of
transmission of 13% as compared to 25% in short
course ZDV at 15 weeks follow-up in Uganda
[8].
The Thailand package is now being promoted by
UNAIDS, WHO and UNICEF as a successful
HIV/AIDS prevention strategy [9]. Some guidance
lists considerable minimum requirements for the
intervention, including the availability of safe and
affordable alternatives to breastfeeding [10], but
another gives an optimistic perspective on the po-
tential benefits and indicates that the intervention
should be implemented [9].
Using published data, this paper explores the po-
ssible consequences on child mortality of imple-
menting these interventions (voluntary testing and
anti-virals with and without artificial feeding) in
middle and low income developing countries. It al-
so examines the possibility that in a context where
most women do not know their HIV status, one of
the effects of promoting the Thai package may be
a reduction of breastfeeding among both HIV posi-
tive and negative women.
MATERIAL AND METHODS
Methods
By constructing two hypothetical (middle and low-
-income) scenarios using published data, we exa-
mined what the net gains of the programme are li-
kely to in low and middle income developing co-
untries (where most vertical transmission takes pla-
ce). [1]
The outcome measure used is the effect on in in-
fant and child deaths, which is appropriate both for
reduced MTCT and the decision whether or not to
breastfeed. Estimates are made to determine what
percentage of a birth cohort the intervention wo-
uld save from dying by their tenth birthday, that is,
a 1% gain would represent prevention of 1,000 de-
aths before age 10 if in a birth cohort of 100,000
competing cause effects are ignored. Breastfeeding
has been associated with other benefits, both for
the child, such as decreased morbidity and higher
scores on intelligence tests, and for the mother,
such as reduced risks of breast and ovarian cancer.
However, for this study we focus on the decreased
risk of mortality in the child as the main benefit
[11].
Data
1. Positive impact: reduced child deaths
The main benefits of the intervention on child
mortality will depend on a number of factors, prin-
cipally:
• degree of HIV seroprevalence among pregnant
women
• their willingness to present for VCT and to return
for the results
• reliability of HIV testing
• compliance with interventions (all stages)
• initial estimates of MTCT
• reduced transmission as a result of the interven-
tions
• case fatality rate (CFR) for HIV positive infants
• life expectancy of survivors, given that they have
an increased risk of being ophaned.
HIV prevalence amongst pregnant women in de-
veloping countries varies greatly [1]. High risk (usu-
ally urban) areas in countries where the program-
me is likely to be promoted can have a prevalences
around 30% and some recent figures include 43%
antenatal HIV prevalence in Francistown, Botswa-
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na; 32% in Harare, Zimbabwe; and 28% in Kwa-
zulu, South Africa [3]. We have assumed a mid-po-
int of 25% and we test the range 5–40% for preva-
lence.
Numbers of HIV-infected women presenting for
HIV testing. Published data, based on experience
from UNAIDS and other trials, have indicated that
around 60% of eligible women present for VCT
[12,13]. The split between HIV-infected and un-in-
fected women is uncertain. If they are genuinely
unaware of their status, a 50–50 split is a reasona-
ble assumption. Our estimate of the proportion of
HIV-infected women presenting for testing ranges
from 20 to 80%.
Numbers of HIV infected returning for test re-
sults is also an important factor, particularly where
there is a delay in results availability. A study in the
Cote d’Ivoire found that a substantial proportion of
women who had been tested did not return for
their results and that this was more likely where
the woman were infected [14]. A range of 40–90%
is examined.
Accuracy of tests. HIV testing is very accurate in
ideal conditions, but in the field there is often no
quality control such as repeat or confirmatory te-
sting. Labelling and transcription errors will occa-
sionally occur. There will therefore be a certain de-
gree of inaccuracy. We have made the assumption
of 95% accuracy.
Numbers complying with treatment. This is
a complex area. Some mothers may not comply
from the start; others may end the treatment early;
others again may share their medication or omit
some doses even in well managed trials [6]. Much
will depend on the organisation of services, their
cost, the convenience of the package and the de-
gree of stigmatisation which may be incurred by
practices which reveal a woman’s status. Currently
only about half of women in developing countries
deliver with the aid of a skilled attendant [15]. It
may therefore be realistic to assume a relatively
low level of compliance with the package. We as-
sume 60% compliance and test a range of 40% to
80%.
Overall MTCT in the absence of treatment varies
with a number of viral, immunological and other
factors such as the mode of delivery, length of rup-
ture of membranes and infant feeding practices
[16]. Estimates from different regions vary from
14–40%, with the lowest rates occurring in Europe-
an countries [16]. For low income scenarios, with
populations almost entirely breastfeeding, we assu-
me an MTCT of 30%. For middle income coun-
tries, we assume that the 80% of women who
commence breast-feeding will have rates of MTCT
of 30%, while non-breastfeeders (20%) will have
15% [2,16,17]. This allows for HIV infected wo-
men who intend to formula feed in developing co-
untries but find difficulties in doing so and end up
breastfeeding [18].
In terms of reduction of transmission, for the full
package (short-course ZDV with artificial feeding)
we use the results of the Thailand trial which, with
good compliance and total non-breastfeeding, re-
sulted in a 50% reduction in MTCT (It should be
noted that the women in this study were not seve-
rely immunosuppressed) [7]. We also consider the
African trial [5,6] option, of providing short-course
ZDV or nevirapine with continued breastfeeding,
in which case a 40% reduction in MTCT is antici-
pated [8].
Case fatality rate amongst HIV-infected infants
will be higher in low income than in middle inco-
me settings. We assume a probability of death of
0.7 by the age of 5 and 0.9 by the age of 10 in low
income countries; in middle income countries, the
equivalent figures are 0.35 and 0.60 [19].
Life expectancy of uninfected children with HIV
infected parents. Children who escaped infection
through the intervention still face an increased like-
lihood of death compared to their peers living in
families free of HIV, for example because of the
adverse effects of orphanhood [20]. Using data
from a cohort study in Kampala, Uganda, and exc-
luding the higher mortality attributable to the trans-
mission of HIV to the infants themselves, we redu-
ce the estimate of beneficiaries by between 1 and
3 times the prevailing CMR in those regions [21].
2. Potential Negative impact: increased child deaths
There are also a number of potential negative con-
sequences of these interventions, which need to be
considered. Probably the most important is a po-
tential reduction in breastfeeding by HIV uninfec-
ted mothers (either false positives, or women who
have attended VCT and not returned for their re-
sults, or amongst the general population of antena-
tal women who have not attended VCT but have
heard about the intervention) [10]. This has been
referred to as ‘spill-over’ of the artificial feeding in-
tervention. The impact of this will depend on:
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• the proportion of HIV uninfected women in the
population who decide not to breastfeed as a re-
sult of the intervention programme
• the increased risk of infant morbidity and morta-
lity through loss of the benefits of breast feeding,
such as inadequate nutrition, lack of immunolo-
gical benefits of breast milk, loss of child-spacing,
diarrhoeal disease etc. These in turn will depend
on factors such as the availability and affordabili-
ty of breast-milk substitutes and access to clean
water [17]. For example in a randomised trial of
breast versus artificial feeding in Nairobi, Kenya,
though artificial feeding reduced MTCT of HIV
there was no difference in child mortality by two
years of age, presumably because of increased
mortality in formula fed children [18].
Proportion of HIV uninfected women who ce-
ase breastfeeding as a result of the a package
including artificial feeding. This is currently
unknown. Much will depend on how the pro-
gramme message is presented and disseminated
and local cultural factors. Least effect might be
expected if the intervention was low-key and all
antenatal women present for VCT and return for
their results and in settings when breast feeding
was already universal. Here even women known
to be HIV infected may be reluctant to use artifi-
cial feeding [18]. At the other end of the scale,
the worst result could be where there was alre-
ady significant use of artificial feeding; where the
programme is well-publicised; where involve-
ment by antenatal women is low; where a large
proportion came for testing and counselling but
failed to receive their results; and if antenatal
HIV testing had a low positive predictive value.
Much will also depend on the pre-existing preva-
lence of breastfeeding and the availability and af-
fordability of artificial feeds [10].
The child mortality rate in the country or region
will strongly influence the extent to which infants
are put at risk by non-breastfeeding. We have used
the under five mortality rate estimates for Central
and Eastern Africa of 140/1,000 for low income
settings and 70/1,000 from Brazil, Thailand, India
and South Africa for middle income. These do not
take into account the effects of HIV/AIDS and
competing risk effects are ignored [3].
In low income settings it is assumed that close to
100% of women will breastfeed their babies in the
absence of the intervention [17]. The concern is
that HIV negative women may be influenced by
promotion of artificial feeding for HIV-infected wo-
men, or by seeing other women feeding babies ar-
tificially. Set against that is the fear of stigmatisation
if artificial feeding becomes a marker for HIV infec-
tion in a woman, and the expense which switching
to artificial feeds might involve [18]. We test a ran-
ge of percentages of women switching away from
breastfeeding, from 1 to 5% of HIV-negative wo-
men.
In middle income countries, artificial feeding is al-
ready more common (we assume a base level ave-
rage prevalence at birth of 20% [17]). The stigma
will therefore be less significant, and artificial feeds
more affordable, and so a more substantial swing
towards artificial feeding might be expected. We
assume 20% of women shift away from breastfe-
eding in this population, if the full Thailand packa-
ge is implemented, and test a range of 10–30%.
It is also likely that some mothers will breastfeed
initially and then stop early or mix feed [17]. Ho-
wever, for simplicity in this analysis we have assu-
med that mothers either breastfeed optimally or
avoid it altogether.
Increased risk of mortality for non-breastfed in-
fants. This is in comparison with optimal breast-fe-
eding infants (exclusive breastfeeding up to at least
4 and if possible 6 months, followed by continued
breastfeeding supplemented by solids up to 12
months). This is the subject of some continued
controversy and a paucity of information. There
are few recent published data, especially from Afri-
can settings, though results of the Kenya breastfe-
eding verses artificial feeding trial implied an incre-
ased risk of dying among HIV uninfected infant re-
ceiving formula feeds [18]. Victora et al. [22,23] fo-
und an increased risk in Brazil of dying of
diarrhoeal disease of 14.2 and of respiratory dise-
ase of 3.6 for infants who do not receive any bre-
astmilk. Kuhn and Stein [24] quote a relative risk
from all causes of mortality in developing countries
of 2.5. A combination of other studies quote a re-
lative risk of non-HIV mortality in the first year of
life of formula-fed infants compared with breastfed
of 3 or 4 [25].
Most of these studies were carried out in middle
income countries with IMRs in the range of
40–50/1,000 births. These probably underestimate
the potential dangers in low income countries with
higher rates of infectious diseases. Golding et al. re-
cently reviewed breast feeding related mortality,
noting many methodological problems in direct
studies of deaths and retrospective studies [25],
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and identified only two reliable prospective popu-
lation studies. Allowing for social factors a study in
Malaysia found a relative risk for post-neonatal in-
fant mortality of non breast feeding of 2 [26]. In
urban Guinea-Bissau children 12–36 months of
age who were no longer having breast milk had an
increased risk (odds ratio) of 2.6, rising to 3.5 (95%
CI, 1.4–8.3) [27].
We assume a conservative value of 2 for the relati-
ve risk of mortality and test a range from 1 (no
change) to 3 for non-breastfed infants in develo-
ping countries. This means an attributable risk of
between 0 and 2. Any protective effect of breast-
-feeding beyond the first year of life is ignored.
RESULTS
The effects of all of the variables analysed are po-
tentially significant – their values will affect the final
balance of benefits and disbenefits of the interven-
tion. Moreover, to illustrate all permutations would
be impossible here and we therefore initially focus
on assumed values at or near the mid-point in the
range for uncertain parameters and then undertake
a sensitivity analysis across the range. Results are
presented for low and medium income settings (or
regions).
Data are shown for estimated benefits in terms of
the proportion of child deaths reduced by the use
of the Thailand (Table 1) and African regimes (Ta-
ble 2). The potential estimated disbenefits of incre-
ased child mortality due to reduced breastfeeding
are then shown in Table 3. All three tables contain
results for low-income and middle income settings.
The net results are presented at the end of Table 3. 
These results indicate that the benefits would be
greater in low income countries (0.49%) than in
middle income countries (0.34%) (Table 1 and 2).
This is primarily attributable to higher MTCT before
the treatment and higher case fatality rates for HIV-
-positive children. In contrast, the potential for in-
creased child deaths is higher in middle income
countries, despite lower child mortality rates in ge-
neral, because of the increased vulnerability to
a spill-over of non-breastfeeding into the HIV-ne-
gative population (Table 3).
Looked at in terms of net benefits using the Tha-
iland regime, low income settings could realize
a small gain in child survival of 0.03%, as against
a potential net loss (increased deaths) for middle
income settings of –1.08%. Considering the African
regime alone although the gains are smaller (0.36%
for low income; 0.26% for middle income) (Table
2), they would not be offset by the estimated losses
due to non-breastfeeding, so that the net gain wo-
uld be larger (Table 3).
The expected effects remaining through each stage
of intervention for the African regime (from Table
2) on a birth cohort of 100,000 in a low income
setting is illustrated in figure 1.
Midpoint figures for variables lowincome
cumulative
%
middle
income
cumulative
%
Seroprevalence among
pregnant women
Proportion of HIV+
presenting for VCT
Proportion completing VCT
Accuracy of testing
Compliance rate
MTCT before treatment
Reduction in transmission
CFR for infected children
Adjustment for higher child
mortality rate
Percentage reduction in
child deaths
25
50
65
95
60
30
40
90
72
25
12.5
8.1
7.7
4.6
1.4
0.56
0.50
0.36
0.36%
25
50
65
95
60
27
40
60
86
25
12.5
8.1
7.7
4.6
1.3
0.50
0.30
0.26
0.26%
Table 2. Benefits from short course ZDV or nevirapine with breast-
feeding (midpoint figures for variables).
(African regime)
Midpoint figures for variables lowincome
cumulative
%1
middle
income
cumulative
%
Seroprevalence among
pregnant women
Proportion of HIV+
presenting for VCT
Proportion completing VCT
Accuracy of testing
Compliance rate
MTCT before treatment
Reduction in transmission
CFR for infected children
Adjustment for higher child
mortality rate
Percentage reduction in
child deaths
1 Rounded up to two significant figures
25
50
65
95
60
30
50
90
72
25
12.5
8.1
7.7
4.6
1.4
0.70
0.63
0.45
0.45%
25
50
65
95
60
27
50
60
86
25
12.5
8.1
7.7
4.6
1.25
0.63
0.38
0.32
0.32%
Table 1. Benefits (Reduction in child deaths) from short course ZDV,
plus abstinence from breastfeeding.
(Thailand regime)
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The numbers of pregnant women needed to test to
save one child’s life is 35 (12,500/360) while the
number needed to treat is 13 (4,631/360). While
these changes on child mortality appear small, they
become more significant when applied to popula-
tions. For example for a low income setting coun-
try such as Zimbabwe with an estimated annual
births of 346,000 [3] the net effect of 0.36% wo-
uld, ignoring competing causes of mortality, avoid
approximately 1,250 deaths for the country’s an-
nual birth cohort by its tenth year.
This analysis undertaken for the zidovudine plus
artificial feeding (Thailand) regime (Table 4) shows
that the net outcome of the interventions are high-
ly sensitive to their success of application. With
this model in both low and middle income setting,
if all other variables remain unchanged, a failure
of women to present for HIV testing, to complete
testing or to comply with treatment – as for exam-
ple happened in the Nairobi trial for artificial fe-
eding [18] – would result in more child deaths
than lives saved (Table 4). If mortality rates are hi-
gher than we have assumed among HIV negative
children born to HIV infected mothers then the
positive effects of the intervention will be undone
in both the low income and high income setting.
Predictably, if the spill-over of the artificial feeding
Short course ZDV or nevirapine only (African regime)
Short course ZDV plus artificial
feeding  (Thailand regime) low income middle income
Baseline result
Seroprevalence %
Proportion presenting for VCT
Proportion completing VCT
Compliance rate
Adjustment for higher CMR
1 x CMR
3 x CMR
Spillover’ of non breastfeeding
Attributable risk of death for non-bf
child
Baseline  result
Seroprevalence %
Proportion presenting for VCT
Proportion completing VCT
Compliance rate
Adjustment for higher  CMR
1 x CMR
3 x CMR
0.
variable
5.00 
40
20
80
40
90
40
80
86
58
1
5
0
2
0.
5.00
40
20
80
40
90
40
80
86
58
03%
net result
-0.33 
0.3
-0.24
0.3
-0.14
0.2
-0.12
0.18
0.12
-0.06
0.31
-0.25
0.45
-0.39
26%
0.07 
0.58
0.14
0.58
0.22
0.5
0.24
0.48
0.43
0.29
-1.
variable
5.00 
40
20
80
40
90
40
80
93
79
10
30
0
2
0.
5.00
40
20
80
40
90
40
80
93
79
08%
net result
-1.33
-0.88
-1.27
-0.88
-1.2
-0.95
-1.18
-0.97
-1.05
-1.1
-0.38
-1.78
0.32
-2.48
36%
0.05
0.41
0.1
0.41
0.16
0.36
0.17
0.34
0.28
0.24
Table 4. Sensitivity analysis on net effect results – a negative value
indicates increased child mortality overall. (keeping other
variables at midpoint values and changing one variable at
a time)
100,000 birth cohort
——— 25% mothers HIV+ 
25,000 born of HIV+ mothers
——— 50% mothers present for test
12,500 born of HIV+ mothers tested
——— 65% return x 95% accurate x 60% comply
4,631 born to mothers who return and comply
——— MTCT of 30% before intervention
1,389 would have been HIV+ if no antiviral given 
——— 40% prevented by anti-viral
555 not born HIV+ as a result of intervention
——— 90% Case fatality of HIV+ at 10 years
500 not HIV+ who would have died by age 10 
——— 14% usual U5MR, plus 14% additional risk of
being child of HIV infected mother
360 survive despite single or double orphanhood
The numbers of pregnant women needed to test to save one child’s life is 35
(12,500 / 360) while the number needed to treat is 13 (4,631/ 360). While these
changes on child mortality appear small, they become more significant when
applied to populations. For example for a low income setting country such as
Zimbabwe with an estimated annual births of 346,000 [3]  the net effect of
0.36% would, ignoring competing causes of mortality, avoid approximately
1,250 deaths for the country’s annual birth cohort by its tenth year.
Figure 1. 
Midpoint figures low income middle income
% women (HIV-) ceasing breast-
feeding as a result of intervention A
Attributable risk of dying for non-bf
children
Child mortality rate
% increase in child deaths
Short course ZDV plus artificial
feeding (Thailand regime)
Short course ZDV alone
(African regime)
Net effects: % reduction in child mortality 
3
1
14
0.42
0.03% decrease
in deaths
0.36% decrease
in deaths
20
1
7
1.4
-1.08% increase
in deaths
0.26% decrease
in deaths
Table 3. Disbenefits (increased child deaths) as a result of non-
breastfeeding by HIV-negative mothers.
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regime is greater than anticipated then the negati-
ve effect is greater, while in middle income set-
tings the only time that the intervention shows
a positive effect is if artificial feeding has no nega-
tive effect compared to breastfeeding (Table 4).
For the African regime (anti-virals plus breastfe-
eding) heightened compliance will substantially in-
crease the improvement in child survival while the
only negative effect comes if the mortality among
HIV negative children born to HIV infected mo-
thers is higher than anticipated. Even if that morta-
lity rate is three times that seen in children born to
uninfected mothers there will still be a net benefit.
DISCUSSION
The magnitude of the these different variables will
have to be assessed for any given context in which
implementation of the package is being conside-
red. HIV prevalence, for example, varies widely,
and both numbers presenting and compliance with
treatment are likely to be quite context-specific.
On the negative side, the relative risk faced by
non-breastfed infants will depend on local condi-
tions, and the manner of implementation of the
package is likely to affect the ‘spill-over’ of the
message.
However, the above estimates suggest that in some
quite plausible circumstances the disbenefits of im-
plementing the Thailand regime (antivirals plus arti-
ficial feeding), considered solely in terms of child
deaths, could be greater than the benefits. This
conclusion is made all the stronger by the fact that
costs have been entirely omitted at this stage, as
have other considerations, such as operational con-
straints, drug resistance and other factors mentio-
ned below [9,28].
This conclusion is reinforced if the deaths are di-
scounted. As the increased deaths from non-bre-
astfeeding occur within the first two years, they
would have a higher present value in relation to
deaths avoided from HIV/AIDS, which occur over
1–12 years [17].
However, it also has to be acknowledged that the-
re are areas of uncertainty relating to some of the
variables considered in this model. In particular,
there is little evidence about the likely ‘spillover’ of
non-breastfeeding in different contexts, and how
this could be minimised. There appears also to be
little consensus about the increased risks faced by
non-breastfed infants and children, and how these
vary in different socio-economic settings. (We have
applied the same rate of additional risk to low and
middle income settings, but this could be challen-
ged on the basis that the risk is likely to be higher
in poorer environments). These are areas which
would benefit from further research and are being
addressed in pilot sites looking at the feasibility of
either treatment regime [29].
Countries which face difficulties financing the Tha-
iland regime may promote alternatives to breastfe-
eding without being able to provide access to relia-
ble VCT, short course ZDV or subsidised breast-
milk substitutes. Abstinence from breastfeeding
may be promoted without assistance for families
with the considerable financial burden and cost in
time and resources that it would bring [30]. Equally
there may be a failure to make available family
planning services to offset the loss of child spacing
due to breastfeeding [27]. These would be likely to
worsen outcomes. On the other hand, the option
of sustaining initial breastfeeding, but introducing
early weaning, might usefully be tested.
These packages also raises other issues, such as:
• whether the intervention will increase the spread
of drug resistance, particularly if antiviral drugs
escape from the antenatal system and are used
in an uncontrolled way (for example, if nevirapi-
ne was given to all pregnant women, irrespective
of their HIV status, as has been suggested) [8].
• the personal and social costs of VCT, especially if
a woman’s status HIV becomes public through
the advertisement of artificial feeding in predo-
minately breastfeeding populations. Isolation, fe-
ar, guilt and loss of self-esteem have been repor-
ted in some cases, and abuse from partners, po-
verty, abandonment and even violence have so-
metimes followed [32].
• the economic implications for governments and
families (see below). Where artificial feeding is
advocated, there is also a considerable time loss
to the mother or other carer, as well as the cost
of providing health care for the child who is like-
ly to suffer more frequently from infectious dise-
ases. This is likely to affect the nutritional status
of other family members.
• the ethical difficulties of preventing MTCT while
leaving infected mothers untreated.
• the opportunity costs of imposing this interven-
tion on antenatal/MCH services, which are alre-
ady under strain in many resource poor coun-
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tries, and possibly diverting resources from other
AIDS prevention work.
• there are also possible positive effects, for exam-
ple from VCT, such as the opportunity to provide
health education on avoiding infection and to re-
duce transmission to sexual partners. These ho-
wever depend on effective counselling and be-
havioural change, which cannot be assumed
[10].
The financial costs of the intervention may be con-
siderable. On the government side, these could in-
clude providing reliable and confidential voluntary
testing and counselling; the antiretroviral drugs and
their administration; basic equipment for safe deli-
veries; counselling and support for infant feeding
for the first two years; and (in some cases) contri-
butions towards the cost of breastmilk substitutes
for the first six months, and other milk products up
to at least one year. Health workers would also ha-
ve to be trained to teach mothers to prepare feeds
as safely as possible. Costs have been estimated at
$11 per person for VCT; $50 for short-course
ZDV; $100–200 for breastmilk substitutes plus the
costs of nutrition counselling and support and food
supplements beyond 6 months. This compares
with annual per capita health budgets of less than
$20 in many low income countries [29]. Equally
however use of nevirapine in the African regime
represents a more cost-effective package since the
cost of the drug alone is only around $4. 00 [8,28].
These requirements may considerably reduce both
feasibility and compliance with the Thailand regi-
me and increase the attractiveness of the simpler
African regime. The costs of preventing a child be-
ing HIV infected are estimated to be $1,109 with
the Thailand regime and $298 with voluntary te-
sting and counselling and nevirapine in the African
regime, equivalent to $41.8 and $11.3 per disabili-
ty adjusted life-year (DALY) gained [28]. The attrac-
tiveness of the African regime could be increased
by use of exclusive breastfeeding which may redu-
ce the risk of HIV transmission [35]. However this
also needs piloting since exclusive breastfeeding is
in fact uncommon, even in developing countries
[17].
CONCLUSION
This article has considered two options for redu-
cing MTCT of HIV/AIDS in low and middle income
settings: a short-course of antiviral drugs, with arti-
ficial feeding (the Thailand regime), and antiviral
regimes alone (the African regime: either short co-
urse zidovudine or using a single dose of nivirapine
given to the mother and newborn, with continued
breastfeeding). It has tried to model the net bene-
fits of these approaches, taking into account the
possibility of a ‘spillover’ of non-breastfeeding into
the HIV-negative population of women under the
Thailand regime.
Using reasonable assumptions about the key varia-
bles, this study found that the disbenefits of the
Thailand regime could outweigh its benefits in so-
me contexts. Benefits increase with the increase in
rates of seropositivity, of HIV-positive women pre-
senting for VCT, of completion of VCT, of com-
pliance with treatment, of vertical transmission
prior to the intervention, and of case fatality for
HIV-infected children. Disbenefits increase as the
‘spill-over’ of the non-breastfeeding message incre-
ases, as the relative risk of dying for non-breastfed
children increases, and as child mortality rates
themselves increase [34].
Ironically, we found that middle income countries,
which are most likely to be able to afford to imple-
ment the package, may suffer most from a drop in
breastfeeding. This is partly because there may be
less stigma attached to non-breastfeeding in conte-
xts where it is less universal, and also because of
the increased affordability of artificial feeds. The
package may accelerate existing trends away from
breastfeeding in those relatively more affluent set-
tings.
Although the African regime with continued breastfe-
eding is less effective in reducing MTCT, it offers con-
siderable advantages in terms of reduced likelihood
of ‘spill-over’ (which could outweigh the gains in ma-
ny contexts), reduced programme costs (especially
with nevirapine), increased simplicity of implementa-
tion, and greater convenience for affected families.
Although there is considerable uncertainty about so-
me of the variables in this model, sensitivity analysis
reinforces this conclusion. However that does not
outweigh the need for careful piloting before wide-
spread implementation [29].
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